TCTP Is an Androgen-Regulated Gene Implicated in Prostate Cancer

Mari Kaarbø1,*, Margrethe L. Storm1,*, Su Qu1, Håkon Wæhre2, Bjørn Risberg2,3, Håvard E. Danielsen2,4,5, Fahri Saatcioglu1,2,6

1 Department of Biosciences, University of Oslo, Oslo, Norway, 2 Institute for Medical Informatics, Oslo University Hospital, Oslo, Norway, 3 Division of Pathology, Oslo University Hospital, Oslo, Norway, 4 Center for Cancer Biomedicine, Oslo University Hospital, Oslo, Norway, 5 Department of Informatics, University of Oslo, Oslo, Norway

Abstract

TCTP has been implicated in a plethora of important cellular processes related to cell growth, cell cycle progression, malignant transformation and inhibition of apoptosis. In addition to these intracellular functions, TCTP has extracellular functions and plays an important role in immune cells. TCTP expression was previously shown to be deregulated in prostate cancer, but its function in prostate cancer cells is largely unknown. Here we show that TCTP expression is regulated by androgens in LNCaP prostate cancer cells in vitro as well as human prostate xenografts in vivo. Knockdown of TCTP reduced colony formation and increased apoptosis in LNCaP cells, implicating it as an important factor for prostate cancer cell growth. Global gene expression profiling in TCTP knockdown LNCaP cells showed that several interferon regulated genes are regulated by TCTP, suggesting that it may have a role in regulating immune function in prostate cancer. In addition, recombinant TCTP treatment increased colony formation in LNCaP cells suggesting that secreted TCTP may function as a proliferative factor in prostate cancer. These results suggest that TCTP may have a role in prostate cancer development.

Introduction

Prostate cancer is the most frequently diagnosed non-cutaneous malignancy and the third leading cause of cancer-related deaths in men in western industrialized countries [1]. The importance of androgens for the development and progression of prostate cancer was shown early in the 20th century. This resulted in significant focus on androgens and the receptor to which they bind, the androgen receptor (AR) [2], and androgen ablation therapy became the main line of therapy. Even though AR and androgen action are critically important aspects in prostate cancer, it has become evident that other signaling pathways, as well as non-genomic and genomic alterations, are involved in the development and progression of prostate cancer [reviewed in [3]].

Translationaly controlled tumor protein (TCTP) is a multifaceted factor which is highly conserved in a number of species. It was originally discovered in a mouse sarcoma cell line as a protein regulated at the translational level [4]. TCTP has since been implicated in a number of important cellular processes, such as cell growth, malignant transformation and inhibition of apoptosis. TCTP is not found exclusively in tumor cells, but has a widespread expression profile that is not restricted to a specific tissue or cell type. However, TCTP expression is generally higher in tumors compared to corresponding normal tissue [reviewed in [5]].

TCTP has an anti-apoptotic role in a number of cell lines (reviewed in [6]). TCTP knockout mice are embryonically lethal with reduced number of cells and a higher incidence of apoptosis in the embryos, highlighting its importance in early development [7,8]. In addition, TCTP has been shown to bind calcium [9–12]; this property may be linked to its anti-apoptotic activity as the concentration of free intracellular calcium is known to increase during apoptosis, triggering a sequence of events leading to cell death [13]. TCTP is engaged in a variety of protein-protein interactions and binds tubulin, Ptk-1, p53 and the guanine nucleotide exchange factor Rheb, amongst others [14]. In addition, TCTP mRNA is highly structured and activates PKR, a protein kinase involved in the inflammatory response [15]. Although these studies offer plausible explanations for the many reported effects of TCTP, the exact mechanisms by which TCTP functions remain to be delineated.

TCTP is also a secreted protein with extracellular functions [16]. The secreted form of TCTP was originally identified by its ability to promote histamine release from basophils in a subset of allergic donors and thus named Histamine Releasing Factor (HRF) [17]. Additionally, TCTP stimulated B-cell proliferation, induced expression of IL-1, IL-6, and immunoglobulin production consistent with a role as a B-cell growth factor [16]. TCTP does not contain an N-terminal signal sequence typical for secreted proteins and is secreted through a non-classical pathway involving
exosomes [18]. Interestingly, nanovesicles secreted from apoptotic endothelial cells that act in a paracrine fashion contain TCTP, further extending the modality of its extracellular action [19].

Recent studies have identified TCTP expression in the human prostate. TCTP was found to be expressed in prostatic tissues from men undergoing surgical adenomectomy for benign prostatic hyperplasia (BPH) and in cell lines derived from normal prostate, such as the cell line PWR-1E, and prostate cancer [12]. TCTP expression was also found to be higher than other calcium binding proteins (CBPs) in the human prostate. In addition, immunohistochemical analyses of normal prostate indicated that TCTP was mainly expressed by the secretory luminal cells and to a smaller degree by the basal cells. TCTP was also identified in prostatic fluids, which suggests that it may have an extracellular role in the prostate [12]. In addition, TCTP may affect proliferation and viability in prostate cancer cells [20]. LNCaP cells treated with siRNA targeting TCTP indicated that knockdown of TCTP increases apoptosis through caspase 3 and caspase 8 and reduces cell proliferation in LNCaP cells [20]. Furthermore, results from a recent study indicate that heat shock protein 27 (Hsp27) interacts with TCTP in prostate cancer cells and protects it from degradation [21]. In addition, TCTP expression levels correlated with disease progression, where it was upregulated in castration resistant prostate cancer (CRPC) [21]. These studies implicate TCTP in prostate cancer; however, there is limited information on its regulation and function in prostate cancer cells.

Here we show that TCTP is regulated by androgens, important survival factors for prostate cancer cells as well as the normal prostate. Ectopic expression of TCTP and its knockdown, as well as experiments with recombinant TCTP, show that it contributes to cell growth and proliferation, implicating it as an important factor in prostate cancer.

Materials and Methods

Ethics Statement

This study was approved by the Regional Ethics Committee, REK Sor-Ost (S-07443a), and material from still living patients was included after their written consent. Use of material from dead patients was permitted by the Ethics Committee. Animal experiments were approved by Case Western Reserve University IACUC guidelines. All steps taken for animal welfare and to

Figure 1. Androgen induces TCTP expression in vitro and in vivo. A. LNCaP cells were either left untreated or treated with the synthetic androgen R1881 (10^{-8} M) for the indicated times. Total RNA was isolated and qPCR analyses were performed. TCTP mRNA expression was normalized to GAPDH. The graph illustrates one representative experiment performed in triplicate with error bars indicating ±SEM, the expression levels are relative to cells treated without androgen (set to 1). The experiment was repeated more than three times. B. Western analyses were performed on whole cell extracts made from cells treated in the absence or presence of R1881 (10^{-8} M) for the indicated time points. The expression levels were normalized to GAPDH. The values presented are relative to untreated samples (set to 1). The graph illustrates data from two experiments performed in triplicate with error bars illustrating ±SEM. C. CWR22 xenografts were grown in nude mice and tumor samples were collected either before (t = 0) or 1, 2 and 4 weeks after castration. Total cell extracts were made and used for western blot analyses. The figure shows one representative blot for TCTP and GAPDH, with relative values of TCTP (t = 0 set to 1) normalized to GAPDH. The differences between the groups were evaluated using two-tailed, paired Student’s t-test compared to non-treated samples, with P<0.05 being considered as significant. Significance is indicated by asterisks; one asterisk indicates P<0.05, two asterisks indicate P<0.01.

doi:10.1371/journal.pone.0069398.g001
minimize suffering were according to IACUC guidelines and have previously been described [22,23].

**Cell Culture**

LNCaP cells were obtained from the American Type Culture Collection (ATCC) and cultured in RPMI 1640 medium supplemented with 10% Fetal Calf Serum (FCS), 2 mM L-glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin (Lonza). The human bronchial epithelial BEAS-2B cell line transformed with SV40 was a generous gift from Sten Mollerup (Department of Toxicology, National Institute of Occupational Health, Oslo, Norway) [24]. BEAS-2B cells were maintained in LHC-9 medium supplemented with 1.8 mg/ml bovine serum albumin (BSA) on plates coated with 0.01 mg/ml fibronectin and 0.03 mg/ml bovine collagen dissolved in PBS.

For both cell lines the culture media was changed every two to three days, and the cells were incubated at 37°C in a humidified 5% CO₂, 95% air incubator. For androgen induction experiments, LNCaP cells were starved for 48 h in RPMI 1640 containing 2% charcoal treated (CT)-FCS, followed by an additional 24 h in RPMI 1640 containing 0.5% CT-FCS prior to treatment with 10⁻⁸ M R1881 (synthetic androgen). R1881 was obtained from NEN.

**Xenograft Experiments**

Transplantation, growth, and harvest of tumors from mice bearing CWR22 xenografts were as described previously [22,23]. CWR22 xenografts were grown in nude mice in the presence of a sustained-release testosterone pellet. After tumor growth, mice were castrated, the testosterone pellets were removed and the regressing tumors were collected at 1, 2, or 4 weeks after castration. Animals were housed and treated according to the IACUC guidelines.

**Quantitative PCR (qPCR)**

Upon harvest, total RNA was extracted from cells using Trizol® reagent (Invitrogen) according to manufacturer’s recommendations. 1–5 µg RNA was used for first-strand cDNA synthesis with the SuperScript II system (Invitrogen) and oligo-dT primers. qPCR analyses were performed on the LightCycler 480...
instrument (Roche) with the LightCycler 480 SYBR Green I Master mix (Roche). A standard curve made from serial dilutions of cDNA was made to calculate the relative amount of the target and reference gene for each sample. These values were then normalized to the relative amount of the reference gene. Primers are available upon request. The differences between the groups were evaluated using a two-tailed, paired Student’s t-test, with \( P < 0.05 \) being considered as significant.

Protein Extraction and Western Analyses

Whole cell extracts were made as previously described [25], resolved by SDS-PAGE and transferred to a PVDF membrane (Bio-Rad). The blotted membrane was blocked in 10% nonfat dry milk in Tris-buffered saline (TBS) containing 0.1% Tween (TBS-Tween) for 1 h followed by incubation with primary antibody in TBS-Tween containing 5% bovine serum albumin (BSA) for 14–16 h at 4°C. Antibodies against either TCTP (1:1000) [12], or GAPDH (1:500) (Santa Cruz) were used. Enhanced Chemiluminescence Western blotting detection reagents (Amersham Biosciences) and analysis system were utilized for the detection of the HRP labelled proteins. For quantification, western blots were digitalized with a scanner machine (Epson Perfection V700 Photo) and the optical density was measured with the software ImageQuant TL (Amersham Biosciences). Human TCTP mouse monoclonal antibody was a generous gift from the group of del Vecchio [12].

RNA Interference

Synthetic siRNA targeting TCTP (target sequence 5'-AAC-CATGACCTGCAGGAAAACA-3') was obtained from Dharmaco, while siRNA for luciferase (target sequence: 5’-AACT-TACGCTGAGTACTTCGA-3’) was from Qiagen. LNCaP cells were seeded in full medium 24 h before transfection. The medium was changed to RPMI 1640 without FCS and antibiotics prior to transfection, and the cells were transfected with 100 nM siRNA per well using Oligofectamine (Invitrogen) according to the manufacturer’s protocol.

Colony Formation Assay

LNCaP cells were transfected with siRNA as described above and plated in 10 cm plates at a density of 10000 cells/well. Colonies were grown for three weeks. LNCaP cells treated with recombinant TCTP were seeded at a density of 2500 cells per well in a six-well plate in RPMI supplemented with 10% FCS.

Figure 3. Downregulation of TCTP expression leads to increased apoptosis in LNCaP cells. LNCaP cells were cultured on coverslips and transfected with siRNA against TCTP or Luciferase (Luc) for 72 h. Apoptosis was induced by 100 nM TG for 36 h during siRNA treatment. After treatment and fixation, apoptotic cell death was detected using the TUNEL assay, cell nuclei were stained with DAPI and cells were visualized using Axioplan imaging microscope. A, Representative pictures of LNCaP cells transfected with either TCTP- or Luc-siRNA for 72 h and treated with DMSO or TG for 36 h during transfection. TUNEL positive cells appear as red spots. Arrows indicate apoptotic cells. B, Quantification of apoptosis incidence. The data show the percentage of nonviable cells after 36 h treatment with TG in cells transfected with TCTP or Luc siRNA. Columns represent the mean of three independent experiments performed in triplicate and bars represent \( \pm \)SEM with *: \( P < 0.05 \) indicating significant difference. doi:10.1371/journal.pone.0069398.g003
Rocrin Tal TCTP, GST, or vehicle control was added every two to three days. Colony formation was assessed after two weeks of growth. Cells were fixed in methanol at 220°C for 30 min, stained with 0.1% crystal violet for 20 min and then washed with MQ water. The area covered by the colonies was quantified using GeneTools software from SynGene.

TUNEL Assay

LNCaP cells were seeded on cover-slips, starved and transfected with siRNA as described above. For thapsigargin (TG) induction, the cells were either treated with vehicle or 100 nM TG for the last 36 h of the 72 h transfection period. To detect apoptosis, a TUNEL In Situ Cell Death Detection Kit (Roche) was used according to the manufacturer's instructions. Fluorescence was detected using an Axioplan2 imaging microscope (Zeiss) and pictures were taken with an AxioCam HRc camera (Zeiss). The number of TUNEL-positive cells was expressed as a percentage of the total number of cells.

Gene Expression Profiling

Total RNA from cells treated with siRNA was isolated using the ThermoFisher Scientific TRIzol® reagent according to the manufacturer's instructions and was analyzed at the Norwegian Microarray Consortium (NMC), Oslo University Hospital, Oslo, Norway. The RNA was amplified using the Illumina® TotalPrep RNA Amplification kit (Illumina). 500 ng total RNA was used in the amplification and labelling reaction. The quality of the cRNA was assessed using a Bioanalyzer. Biotin labelled cRNA (1.5 μg) was then used to hybridize onto Illumina Human-6 v3 Expression beadchips using the Whole-Genome gene Expression Direct Hybridization assay from Illumina. After scanning, the results were imported into Illumina BeadStudio, where the quality of each array and scan were tested.

Generation of and Treatment with Recombinant TCTP

The open reading frame (ORF) of hTCTP was cloned into pET-28a for expression of recombinant TCTP. 0.1 mM IPTG was used to induce expression, and following harvest the pellet was resuspended in binding buffer (20 mM NaH2PO4, 500 mM NaCl, 20 mM imidazol, pH 7.4). Protease inhibitors were added and the cell suspension was sonicated at 4°C. His-tagged hTCTP was purified under native conditions using a HiTrap™ Chelating HP Column (GE Healthcare) charged with Ni2+-ions according to the manufacturer’s instructions. The sample was sterile filtered and diluted with binding buffer prior to application onto the column. The column was washed with binding buffer until the absorbance (280 nm) stabilized. Bound proteins were then eluted with elution buffer (20 mM NaH2PO4, 500 mM NaCl, 500 mM imidazol,
The purification procedure was performed at 4°C to prevent protein degradation. The eluate was dialyzed against PBS using Slide-A-Lyzer 10K dialysis cassettes with a cut-off value of 10 kDa. To obtain recombinant GST, pGEX-4T was grown in BL21 cells, induced with 0.1 mM IPTG and purified by incubation with 50% Glutathione Sepharose 4B slurry. The beads were washed with PBS before elution (50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0). The purified proteins were run alongside Precision Plus Dual color Protein Standard, Prestained Protein Markers, Broad Range (7–175 kDa) and Unstained Protein Markers, Broad Range (2–212 kDa) (Biorad) to estimate the amount of protein.

BEAS-2B cells were treated with recombinant TCTP/GST for one h before harvest.

Immunohistochemistry

Tissue microarrays (TMA) were prepared from radical prostatectomy specimens from patients operated at the Norwegian Radium Hospital between 1988 and 1996 and followed up after surgery. Prostate-specific antigen (PSA) measurements were performed before and after operation and at every subsequent clinical examination. Follow-up periods ranged from 2 to 176 months (mean, 73.3 months). Patients were considered to have clinically evident recurrence of disease if any of the following were present: (a) evidence of local recurrence (confirmed by histological biopsies or ultrasound) or (b) evidence of distant metastasis (detected by skeletal scintigraphy and/or magnetic resonance imaging). If a patient who suffered from relapse had postoperative serum PSA of >4 ng/ml before the date of either local recurrence or metastasis, the date of elevated PSA was set as the relapse date. H&E-stained sections were made from each selected primary tumor block (donor blocks) of paraffin-embedded material to define representative tumor regions. With the use of the tissue array instrument (Beecher Instruments), two tissue cylinders (0.6 mm in diameter) were punched from regions of the donor block. Control samples of non cancer tissue from the paraffin blocks were also taken. The Gleason score used in the analysis was the highest Gleason score in each of the prostatectomy series.

The TMAs were first de-paraffinized by xylene and serial ethanol dilutions and washed in H2O prior to quenching of endogenous peroxidase in 0.3% H2O2 in H2O for 30 min. Antigen retrieval was carried out by autoclaving at 121°C for 20 min in 0.01 M citrate buffer (pH 6.4). The BioGenex Super Sensitive Link-Label IHC Detection kit (BioGenex) was used for antigen detection. The sections were equilibrated in TBS-Tween (0.05 M Tris, pH 7.5, 0.3 M NaCl, 0.1% Tween 20) for 5 min prior to incubation overnight at 4°C with anti-human TCTP.
mouse monoclonal antibody diluted 1:100 in TBS-Tween with 1% BSA. Sections were then washed with TBS-Tween prior to incubation with biotinylated secondary anti-mouse IgG (link) for 30 min at room temperature. After wash in TBS-Tween, the secondary antibody was incubated with enzyme HRP-labeled streptavidin for 30 min at room temperature. The slides were then washed in TBS-Tween and stained with DAB for 5 min and the reactions were stopped in H2O. Counterstain was performed by haematoxylin (DAKO) staining and the slides were mounted with DAKO Faramount aqueous mounting medium. Mouse non-immune serum was applied as negative control. Normal prostate tissue sections were used as positive controls. Intensity was scored using a 0–3 scale, corresponding to absent, weak, moderate, and intense staining, respectively. The differences between the groups were evaluated using a two-tailed, unpaired Student’s t-test, with $P < 0.05$ being considered as significant.

**Statistics**

Except for the microarray analyses, statistics were carried out using Student’s t-test where $p$ values $< 0.05$ were considered significant.

**Statistical analysis of gene expression data.** Statistical analysis was performed based on summary expression values for each probe and normalized by quantile normalization which results in the chips having identical intensity distribution. The data were analyzed by J-Express v2.7 software (http://www.molmine.com). Statistical Analysis of Microarrays (SAM) and Feature Subset Selection (FSS) were used for statistical analyses.

**Results**

**TCTP Expression is Induced by Androgens**

We first investigated the possible regulation of TCTP expression by androgens in the androgen responsive prostate cancer cell line LNCaP in a time course experiment. As shown in *Figures 1A and*
1B, there was an androgen-induced increase in both TCTP mRNA and protein accumulation over time, which reached approximately four-fold higher levels compared with untreated cells at 48 h. To determine if TCTP expression is also regulated by androgens in vivo, we used the human androgen-dependent prostate cancer xenograft model CWR22 which markedly regresses after castration [22,23]. Western analysis of CWR22 tumors collected from mice at different time points after castration showed that the TCTP expression significantly decreased in a time-dependent manner and was nearly lost at four weeks (Figure 1C). These results show that TCTP expression is regulated by androgens in prostate cancer cells both in vitro and in vivo.

**Knockdown of TCTP Decreases Colony Formation of LNCaP Cells**

Androgen regulation of TCTP expression, as presented above, suggested that it may have a role in growth of prostate cancer cells. This could either be through the induction of proliferation or inhibition of apoptosis, or a combination of both. To investigate the possible role of TCTP in cell growth, its expression was inhibited in LNCaP cells by siRNA treatment and colony formation was assessed compared with control siRNA treated cells. As shown in Figure 2A, TCTP protein expression was reduced by 85% after 72 h of transfection with siRNA targeting TCTP. Colony formation of TCTP knockdown cells was decreased by 50% compared with control cells (Figures 2B and 2C). These data indicated that TCTP may have a role in LNCaP cell proliferation and/or viability.

**Down-regulation of TCTP Increases Apoptosis of LNCaP Cells**

TCTP was previously reported to inhibit apoptosis in a number of cell lines [20,26–28]. In addition, RNAi-mediated knockdown of TCTP in LNCaP cells activated caspase 3 and caspase 8, indicative of increased apoptosis [20,21]. We thus investigated the possible role of TCTP on apoptosis in LNCaP cells. Previous work from our laboratory has established that Thapsigargin (TG) induces significant apoptosis after 36 h of treatment in LNCaP cells [25]. We thus determined whether TCTP may alter TG-induced apoptosis. LNCaP cells were transfected with either siRNA against TCTP or control (Luciferase) siRNA, then left untreated or exposed to TG, after which the extent of apoptosis was determined using the TUNEL assay. As shown in Figures 3A and 3B, in the absence of TG treatment, there was an approximately three-fold increase in apoptosis in TCTP knockdown cells compared with control cells. As expected, TG significantly increased apoptosis in both control or TCTP-siRNA treated cells, however, it was approximately 2.5-fold higher upon TCTP knockdown. The knockdown of TCTP was verified by qPCR for all experiments (data not shown). These data suggest that TCTP is involved in regulating apoptosis in prostate cancer cells.

**Down-regulation of TCTP Results in Upregulation of Immune Response Genes in LNCaP Cells**

In order to elucidate the pathways TCTP may affect in prostate cancer cells, we conducted a global gene expression profiling in TCTP knockdown cells compared with control LNCaP cells. Significant TCTP knockdown was confirmed at both mRNA and
protein level (data not shown). The data were analyzed using two methods: the Statistical Analysis of Microarrays (SAM) and Feature Subset selection (FSS) tools implemented in J-Express [29]. Out of the 15 most significantly regulated genes determined by each analysis, nine were found to be significant by both methods, as illustrated in the Venn diagram in Figure 4A. Figure 4B shows up- or down-regulation of some of the genes, while a list over the most significantly regulated genes on the array, their ontology, known function and definition are depicted in Figure 4C. The majority of the genes predicted to be significantly regulated upon TCTP knockdown are involved in the interferon signaling pathway and/or immune-related responses. The expression of six of these genes (ITIF1, SLITRK3, IFH41L, ITIF3, OAS2 and MX1) was validated by qPCR (Figures 5A–F). These results imply that TCTP modulates immune responses in prostate cancer cells.

Recombinant TCTP Induces Prostate Cancer Cell Growth

The secreted form of TCTP has previously been shown to induce expression of several mediators, initiate distinct signaling events and lead to an increase in cell proliferation of immune cells [30–32]. Since TCTP is present in prostatic fluids [12], it may have an extracellular function in prostate cancer cells. To assess this possibility, we made recombinant TCTP (rTCTP) in E. coli and determined its biological activity in BEAS-2B cells compared with recombinant glutathione S-transferase (rGST) as a control [33]. BEAS-2B cells were treated with rTCTP or rGST at a final concentration of 1.0 μg/ml for 1 h and IL-8 mRNA production was determined by qPCR. IL-8 mRNA expression was significantly increased in cells treated with rTCTP compared to cells treated with rGST (Figure 6A) indicating that the rTCTP is biologically active. LNCaP cells were then treated with 1.0 μg/ml rTCTP or rGST and a colony formation assay was performed. After two weeks in culture with continuous exposure to the recombinant proteins, cells were fixed and stained to visualize colonies. As shown in Figures 6B and 6C, there were a significantly higher number of colonies formed by the cells treated with rTCTP compared to rGST-treated cells. These data indicate that rTCTP has a proliferative/pro-survival effect on LNCaP cells and suggest a role of secreted TCTP in prostate cancer cell growth.

TCTP Expression is Upregulated in Prostate Cancer Compared to Normal Prostate

Since TCTP is expressed in the normal prostate, as well as regulated by androgens in prostate cancer cells in vivo and in vitro, we investigated its expression on tissue microarrays (TMAs) containing normal prostate tissue as well as those representing various stages of prostate cancer using immunohistochemistry (IHC). As shown in Figure 7A, TCTP was expressed primarily in epithelial cells in both normal prostate and prostate cancer. Furthermore, its expression was significantly increased in cancer tissue compared with normal cells (Figure 7B), which indicates that TCTP may have a role in prostate cancer.

Discussion

TCTP is a highly conserved protein in eukaryotes, from yeast to mammals, and abundantly expressed in a wide range of tissues (for a review, see 5). Several studies have underscored the multiple processes TCTP is involved in, such as immune responses, cell proliferation, tumorigenicity, and cell death [5]. The data presented here establish TCTP as an androgen regulated gene implicated in prostate cancer.

Androgen signalling and AR are critical for all phases of prostate cancer [34]. We found that TCTP is a novel androgen regulated gene whose expression is induced at both mRNA and protein level by androgens (Figures 1A and 1B). Furthermore, upon castration, the expression of TCTP dramatically declined in CWR22 androgen dependent xenografts grown in nude mice, indicating that its expression is regulated by androgens also in vivo (Figure 1C). Since androgens increase proliferation and inhibit apoptosis, which is the same outcome as observed in our experiments by TCTP manipulation, it is tempting to speculate that growth and viability regulating effects of androgens, at least in part, may be mediated by TCTP.

TCTP depletion in LNCaP cells significantly increased both basal levels of apoptosis, consistent with previous findings [20], as well as TG- induced apoptosis (Figure 3). These findings are consistent with a recent study that developed a TCTP antisense oligonucleotide (ASO) which inhibited the growth of PC-3 and LNCaP xenografts and significantly enhanced docetaxel activity upon systemic delivery [21]. These data open up the possibility for using TCTP knockdown in parallel with other established therapeutic approaches to increase treatment efficacy.

Gene expression profiling data indicated that approximately 60% of the differentially regulated genes are involved in the interferon (IFN) pathway (Figure 4). IFNs are a family of cytokines, named for their ability to interfere with viral infection. They mediate antiviral and antigrowth responses and are also known to modulate adaptive immune responses [35]. These findings are interesting given that TCTP was recently found to interact with NEMO, an upstream adaptor protein in the NF-κB pathway, and that NF-κB regulates transcription of inflammatory and survival genes [36]. In pilot experiments we observed that the NF-κB pathway is activated upon TCTP knockdown in LNCaP cells consistent with the notion that TCTP regulates immune responses in prostate cancer (data not shown). The IFN stimulated genes have been implicated in several cancers, including prostate cancer; however, what specific role they play in the different cancers and at what disease stage are currently unknown [37–42]. Interestingly, the IFN stimulated genes were not affected by androgen induction in LNCaP cells (data not shown); this could mean that TCTP may collaborate with other factors that are not regulated by androgens. Alternatively, since androgen induction of TCTP takes at least 48 h, longer time exposure to androgens may be needed to observe any effects on IFN pathway related genes. Further work is necessary for determining the possible consequence of IFN gene expression changes on PCs cell growth and viability.

The secreted form of TCTP is well-studied in immune cells, where it has been shown to function as a histamine releasing factor, induce secretion of various interleukins, initiate distinct signal transduction events, and affect cell proliferation (reviewed in [16]). Since TCTP was earlier found in prostatic fluids [12], it was suggested to have a role in prostate function and in prostate cancer; however, there have not been any studies to date which addressed the possible effect of rTCTP on prostate cancer cells. Consistent with the other data presented herein, and the function of TCTP in immune cells, we found that rTCTP increased colony formation in LNCaP cells (Figure 6). This indicates that the proliferative effects of secreted TCTP is not restricted to immune cells and is also applicable to prostate cancer cells. rTCTP has previously been implicated in the induction of distinct signal transduction pathways in immune cells [30,32]; it is therefore of interest to investigate whether this is also the case in prostate cancer cells. Further studies elucidating the molecular mechanisms behind these results are therefore warranted.
TCTP was previously found to be expressed in normal prostate and prostate cancer cells [12,21]; it was also found to be further increased in castration resistant prostate cancer [21]. In line with these findings, we found a significant increase in TCTP expression in a TMA representing a collection of prostate cancer samples from various cancer stages compared with benign prostate (Figure 7). These data are consistent with earlier findings where TCTP was suggested to be involved in the process of initiation and progression of castration resistant prostate cancer [21].

Taken together, our data and earlier findings suggest that TCTP expression is relevant for human prostate cancer. TCTP may have a unique role in regulating inflammation and carcinogenesis processes thought to be tightly linked, making it a potential biomarker and a therapeutic target in prostate cancer.

References

1. Jamal K, Patel P, Sooriakumaran P (2008) Minimally invasive surgical modalities in the management of localized prostate cancer. Expert Rev Anticancer Ther 8: 957–966.
2. Huggins C, Hodges CV (1941) Studies on prostatic cancer: effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297.
3. Kazerooni M, Kekki T, Saatcioglu F (2007) Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays 29: 1227–1238.
4. Yenofsky R, Bergmann I, Brawerman G (1982) Messenger-RNA Species Partially Structured RNA, which activates the dsRNA-dependent protein kinase in a Repressed State in Mouse Sarcoma Ascites-Cells. Proceedings of the National Academy of Sciences of the United States of America-Biological Sciences 79: 5876–5880.
5. Nagano-Ito M, Ichikawa S (2012) Biological effects of Mammalian translationally controlled tumor protein (TCTP) on cell death, proliferation, and tumorigenesis. Biochem Res Int 2012: 204960.
6. Chan TH, Chen L, Guan XY (2012) Role of translationally controlled tumor protein in cancer progression. Biochem Res Int 2012: 569054.
7. Chen SH, Wu PS, Chou CH, Yan YT, Liu H, et al. (2007) A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell type-specific manner. Molecular Biology of the Cell 18: 2253–2302.
8. Susini I, Besse S, Duflant D, Lespagnon A, Beekman C, et al. (2000) TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ.
9. Haghshigh NG, Ruben L (1992) Purification of Novel Calcium-Binding Proteins from Trypanosoma-Brucii - Properties of 22-Kilodalton, 24-Kilodalton and 38-Kilodalton Protein. Molecular and Biochemical Parasitology 51: 99–110.
10. Kim M, Jung Y, Lee K, Kim C (2009) Identification of the calcium binding sites in translationally controlled tumor protein. Archives of Pharmacal Research 23: 633–636.
11. Sanchez JC, Schaller D, Ravix F, Golaz O, Jaccoud S, et al. (1997) Translationally controlled tumor protein: a protein identified in several mammotumors including erythrocytes. Electrophoresis 18: 150–155.
12. Arcuri F, Papa S, Carducci A, Romagnoli R, Liberatori S, et al. (2004) Translationally controlled tumor protein (TCTP) in the human prostate and prostate cancer cells: Expression, distribution, and calcium binding activity. Prostate 60: 130–140.
13. McConkey DJ, Orruenu S (1997) The role of calcium in the regulation of apoptosis. Biochem Biophys Res Commun 239: 357–366.
14. Amsen R, Pece S, Marine JC, Fiore PP, Telerman A (2013) TTP1/TCTP-regulated pathways in phenotypic reprogramming. Trends Cell Biol 23: 37–46.
15. Bonmer UA, Borovojgin AV, Greagg MA, Jeffrey RW, Russell P, et al. (2002) The mRNA of the translationally controlled tumor protein P23/TCTP is a highly structured RNA, which activates the dsRNA-dependent protein kinase PKR. RNA 8: 473–476.
16. Macdonald SM (2012) Potential role of histamine releasing factor (HRF) as a therapeutic target for treating asthma and allergy. J Asthma Allergy 5: 51–59.
17. Macdonald SM, Rafnar T, Langdon J, Lichtenstein LM (1995) Molecular Identification of an IgE-dependent histamine-releasing factor. Science 269: 680–690.
18. Amzlaz Z, Passer BJ, Allican D, Segura E, Thiery C, et al. (2004) TSAP6 facilitates the secretion of translationally controlled tumor protein/histamine-releasing factor via a nonclassical pathway. Journal of Biological Chemistry 279: 46104–46112.
19. Siros I, Raymond MA, Brassard N, Caillier JF, Fedjare M, et al. (2011) Caspase-3-dependent export of TCTP: a novel pathway for antiapoptotic intercellular communication. Cell Death and Differentiation 18: 549–562.
20. Zhang X, Pan X, Yang Y, Cai L, Zeng J, et al. (2008) Gene silencing of translationally controlled tumor protein (TCTP) by siRNA inhibits cell growth and induces apoptosis of human prostate cancer cells. International Journal of Oncology 34: 1241–1246.
21. Baylot V, Katsogianou M, Andreiu C, Taieb D, Aruemo J, et al. (2012) Targeting TCTP as a New Therapeutic Strategy in Castration-resistant Prostate Cancer. Molecular Therapy 20: 2244–2256.
22. Wainstein MA, He F, Robinson D, Kang HJ, Schwartz S, et al. (1994) CWR22: androgen-dependent xenograft model derived from a primary human prostate carcinoma. Cancer Res 54: 6839–6852.
23. Nagahabashian M, Miller GM, Pedlow TP, Giaconia JM, Edgheosue NL, et al. (1996) CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 56: 3042–3046.
24. Lechner JP, Haugen A, McClendon Jr, Pettis EW (1982) Clonal Growth of Normal Human Bronchial Epithelial-Cells in a Serum-Free Medium. In: Vitro-Journal of the Tissue Culture Association 18: 633–642.
25. Engedal N, Korkmaz CG, Saatcioglu F (2002) C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP. Oncogene 21: 1017–1027.
26. Yang Y, Yang F, Xiong ZY, Yan Y, Wang XM, et al. (2005) An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene 24: 4778–4780.
27. Zhang D, Li F, Wieder D, Manjovan ZH, Fujico K (2002) Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and fortlin - The potential role of MCL1 as a fortlin chaperone. Journal of Biological Chemistry 277: 37430–37438.
28. Li F, Zhang D, Fujico K (2001) Characterization of fortlin, a novel antiapoptotic protein. Journal of Biological Chemistry 276: 47542–47549.
29. Dysvik B, Jonassen I (2001) Expression analysis using microarrays - J-Express: exploring gene expression data using Java. Bioinformatics 17: 369–370.
30. Vonakis BM, Macglashan DW Jr, Valiarno N, Langdon JM, Scott RS, et al. (2008) Distinct characteristics of signal transduction events by histamine-releasing factor/translationally controlled tumor protein (HRF/TCTP)-induced priming and activation of human basophils. Blood 111: 1789–1796.
31. Kang HS, Lee MJ, Song H, Han SH, Kim YM, et al. (2001) Molecular identification of IgE-dependent histamine-releasing factor as a B cell growth factor. Journal of Immunology 166: 6545–6554.
32. Vonaki BM, Gibbons S, Sora K, Langdon JM, MacDonald SM (2001) Srr homology 2 domain-containing mostol 5 phosphatase is negatively associated with histamine release to human recombinant histamine-releasing factor in human basophils. Journal of Allergy and Clinical Immunology 108: 822–831.
33. Yoneeda K, Rokutan K, Nakamura Y, Yanagawa H, Kontdo-Teshima S, et al. (2004) Stimulation of human bronchial epithelial cells by IgE-dependent histamine-releasing factor. American Journal of Physiology-Lung Cellular and Molecular Physiology 286: L174–L181.
34. Nelson PS (2012) Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate Cancer. Journal of Clinical Oncology 30: 644–646.
35. Malmgaard L (2004) Induction and regulation of IFNs during viral infections. Journal of Interferon and Cytokine Research 24: 439–454.
36. Fenner BJ, Scannell M, Prehn JHM (2010) Expanding the Substantial Interactome of NEMO Using Protein Microarrays. Plos One 5.
37. Madigan AA, Sobek KM, Cummings JL, Green WR, Baech DJ, et al. (2012) Activation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasia. Genes and Immunity 15: 562–576.
38. Duarte CW, Willey CD, Zhi D, Cui X, Harris JJ, et al. (2012) Expression Signature of IFN/STAT1 Signaling Genes Predicts Poor Survival Outcome in Glioblastoma Multiforme in a Subtype-Specific Manner. Plos One 7.
39. Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, et al. (2006) Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia 8: 862–878.
40. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, et al. (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proceedings of the
41. Marra E, Uva P, Viti V, Simonelli V, Dogliotti E, et al. (2010) Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways. Bmc Cancer 10.

42. Heinonen H, Nieminen A, Saarola M, Kallioniemi A, Klefstrom J, et al. (2008) Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. Bmc Genomics 9.